Lixte Biotechnology (NASDAQ:LIXT) Shares Up 4.2% – Time to Buy?

Shares of Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) rose 4.2% during trading on Friday . The stock traded as high as $7.99 and last traded at $7.51. 614,310 shares changed hands during mid-day trading, an increase of 21% from the average daily volume of 506,337 shares. The stock had previously closed at $7.21.

Analyst Ratings Changes

A number of analysts have issued reports on LIXT shares. Wall Street Zen raised Lixte Biotechnology to a “hold” rating in a research note on Saturday, June 13th. Weiss Ratings lowered shares of Lixte Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, May 26th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.

Lixte Biotechnology Stock Performance

The stock’s fifty day moving average is $7.31 and its 200 day moving average is $4.88. The stock has a market cap of $112.80 million, a P/E ratio of -6.65 and a beta of 1.24.

Lixte Biotechnology (NASDAQ:LIXT) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.18) earnings per share for the quarter.

Institutional Trading of Lixte Biotechnology

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Axxcess Wealth Management LLC purchased a new position in Lixte Biotechnology during the fourth quarter worth $54,000. XTX Topco Ltd purchased a new stake in shares of Lixte Biotechnology in the fourth quarter valued at $57,000. Geode Capital Management LLC lifted its holdings in shares of Lixte Biotechnology by 25.9% in the 4th quarter. Geode Capital Management LLC now owns 52,163 shares of the company’s stock worth $205,000 after acquiring an additional 10,722 shares during the last quarter. DRW Securities LLC lifted its holdings in shares of Lixte Biotechnology by 11.6% in the 4th quarter. DRW Securities LLC now owns 54,126 shares of the company’s stock worth $213,000 after acquiring an additional 5,645 shares during the last quarter. Finally, FNY Investment Advisers LLC purchased a new position in shares of Lixte Biotechnology during the 2nd quarter worth about $330,000. Hedge funds and other institutional investors own 5.10% of the company’s stock.

Lixte Biotechnology Company Profile

Lixte Biotechnology Holdings, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for the treatment of cancer. The company’s research centers on selectively targeting key enzymes and pathways involved in DNA damage response and cell cycle regulation, with the goal of creating novel oncology drugs that improve patient outcomes with manageable safety profiles.

Lixte’s lead programs include selective inhibitors of cell cycle checkpoints and related targets, designed to potentiate the effects of standard-of-care chemotherapies and overcome resistance mechanisms.